Mr. C.K. Cheung reports

EVITRADE HEALTH SYSTEMS SIGNS DEFINITIVE AGREEMENT TO BRING BEST OF BREED SCIENCE TO THE CANNABIS INDUSTRY

Evitrade Health Systems Corp. has signed a definitive agreement with Cantech Molecular Research Inc.

"On the heels of our letter of intent with Cantech, we are pleased that Evitrade has reached final terms on the definitive agreement," said C.K. Cheung, chief executive officer of Evitrade. "We are thrilled to have the world-class talents of Malcolm Lamont and his associates of Cantech on board with us. Malcolm's history and cutting-edge research into systems within plant science and genetics with large international plant seed supply and breeding firms will help put Evitrade at the top of the industry for the creation of superior breeding protocols and benchmarks in plant genetics."

Among the many progressive capabilities Evitrade will gain with the Cantech acquisition is the ability to produce true homozygotic plants with a highly select and consistent set of traits. These can be used for a multitude of purposes such as: plants with tailored CBD/THC (cannabidiol/tetrahydrocannabinol) combinations for a given illness but more importantly the company's plants will allow repeatability and consistency for the marketplace.

As Canada turns to enact legislation to legalize adult use and improve laws for medical cannabis use, the possibilities for this technology are abundant.

Management continues to strive to seek optimal business and commercialization strategies for the company. This, with the continued relationship with Haywood Securities as financial adviser, has the company planning forward for a bright future.

About Evitrade Health Systems Corp.

Evitrade (formerly Auxellence Health Corp.) was founded in 2013 to provide on-line digital health care services for resolving common health problems. The current markets are weight loss, high blood pressure, high blood glucose and heart arrhythmia.

We seek Safe Harbor.